Published in Clin Transl Oncol on September 01, 2011
Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology (2011) 0.95
Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force. Asia Pac J Clin Oncol (2014) 0.83
Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol (2016) 0.81
Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol (2015) 0.77
Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. J Natl Cancer Inst (2014) 0.76
HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges. Clin Transl Oncol (2011) 0.76
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 15.17
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res (2008) 6.95
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol (2008) 5.78
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol (2006) 5.56
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol (2008) 5.28
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med (2002) 5.25
The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell (2011) 4.79
Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene (2002) 4.20
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst (2007) 4.03
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst (2008) 3.60
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44
High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell (2007) 3.27
Isolation and in vitro expansion of human colonic stem cells. Nat Med (2011) 3.20
A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol (2009) 3.12
Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet (2011) 3.06
Global human footprint on the linkage between biodiversity and ecosystem functioning in reef fishes. PLoS Biol (2011) 3.02
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol (2010) 3.00
Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell (2012) 2.94
Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res (2006) 2.73
4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res (2007) 2.67
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther (2009) 2.61
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol (2005) 2.54
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J (2003) 2.39
Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res (2006) 2.34
Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem (2004) 2.33
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet (2007) 2.33
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol (2010) 2.31
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol (2002) 2.25
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol (2002) 2.25
A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res (2007) 2.11
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat (2006) 2.10
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol (2007) 2.10
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res (2004) 2.04
β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med (2012) 2.02
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics (2012) 2.01
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist (2012) 1.96
Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet (2012) 1.81
Adenomatoid tumors of the uterus: an analysis of 60 cases. Int J Gynecol Pathol (2002) 1.80
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A (2004) 1.77
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol (2010) 1.74
Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene (2003) 1.74
A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn (2010) 1.71
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res (2006) 1.70
Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer (2006) 1.68
Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J Clin Oncol (2009) 1.65
Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery (2005) 1.64
Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol (2010) 1.63
The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer (2011) 1.62
Chromatin-bound IκBα regulates a subset of polycomb target genes in differentiation and cancer. Cancer Cell (2013) 1.61
Expanded cells in monoclonal TCR-alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood (2008) 1.61
The morphological and molecular features of the epithelial-to-mesenchymal transition. Nat Protoc (2009) 1.60
Keratinocyte dysplasia: an usual finding after transplantation or chemotherapy. J Cutan Pathol (2002) 1.60
External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist (2011) 1.59
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res (2002) 1.57
Comparison of molecular analysis and histopathology for axillary lymph node staging in primary breast cancer: results of the B-CLOSER-I study. Diagn Mol Pathol (2012) 1.56
A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol (2009) 1.54
Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. Arch Pathol Lab Med (2012) 1.53
Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res (2006) 1.53
Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene. J Natl Cancer Inst (2005) 1.50
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol (2004) 1.49
Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol (2012) 1.48
Institutional declaration in favour of the development of interdisciplinary cancer care in Spain. Clin Transl Oncol (2010) 1.47
Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene (2002) 1.46
Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis. J Mol Diagn (2012) 1.44
Microbiological contamination in stem cell cultures. Cell Biol Int (2007) 1.43
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer (2003) 1.43
Nesfatin-1 in human and murine cardiomyocytes: synthesis, secretion, and mobilization of GLUT-4. Endocrinology (2013) 1.41
Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene (2003) 1.41
Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol (2012) 1.40
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2006) 1.40
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res (2012) 1.39
Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene (2004) 1.39
[1st National Meeting of Multidisciplinary Work in Oncogeriatrics: expert consensus document]. Rev Esp Geriatr Gerontol (2012) 1.39
SEOM guidelines for endometrial cancer. Clin Transl Oncol (2012) 1.38
Key contribution of CPEB4-mediated translational control to cancer progression. Nat Med (2011) 1.37
Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res (2007) 1.36
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res (2003) 1.35
Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem (2006) 1.34